LDN for Autoimmune Conditions: What Has Actually Been Studied?

Low Dose Naltrexone, commonly called LDN, is widely discussed in autoimmune and functional medicine communities. Search online and it may appear that LDN has been studied as a single treatment for nearly every autoimmune condition.

The research tells a more complicated story.

“Autoimmune disease” is an umbrella term, not one diagnosis. Multiple sclerosis affects the central nervous system. Rheumatoid arthritis targets joints. Sjögren’s syndrome primarily affects moisture producing glands and may involve other organs. Psoriasis affects the skin and may involve joints. Crohn’s disease is more accurately described as an immune mediated inflammatory bowel disease.

These conditions do not have the same clinical endpoints, standard treatments, risks, or LDN evidence.

The Direct Answer

LDN has been studied in a few autoimmune and immune mediated conditions, but the evidence is small, uneven, and condition specific. Crohn’s disease has some of the most direct clinical research, including a small placebo controlled adult trial with endoscopic outcomes. Multiple sclerosis has small trials with mixed quality of life findings but no proof that LDN changes the disease course. Evidence for rheumatoid arthritis, Sjögren’s syndrome, and psoriasis is mainly observational or uncontrolled. Condition specific human trial evidence for Hashimoto’s disease and lupus remains insufficient to support routine use.

A broad 2026 review evaluated 105 LDN studies across many indications and concluded that current evidence does not support routine clinical use. The authors noted that encouraging findings from early or uncontrolled studies were often not confirmed in placebo controlled research. The review was later corrected to revise statements in its introduction involving mechanistic research, but the correction did not reverse its overall clinical conclusion. Read the 2026 review and the published correction.

Why Patients Choose Scripx

✔ Digestive Health Resources

✔ Provider-Supported Wellness

✔ Prescription Parasite Medication Education

✔ Nationwide Shipping

✔ Functional Medicine & Longevity Focus

👉 Explore Our LDN Product line HERE

LDN Autoimmune Evidence at a Glance

Condition	What has been studied?	What was reported?	What the evidence does not establish
Crohn’s disease	Small adult and pediatric trials, plus uncontrolled IBD studies	Some clinical and endoscopic response signals	Proven remission benefit, long term control, or equivalence to established therapy
Multiple sclerosis	Two small placebo controlled crossover trials, an open label progressive MS study, and observational research	Mixed quality of life findings and a possible spasticity signal	Slower progression, fewer relapses, or replacement of disease modifying therapy
Rheumatoid and inflammatory arthritis	Prescription database study and a small mixed arthritis pain trial	Reduced medication dispensing in persistent LDN users, but no convincing pain benefit in the small trial	Direct improvement in joint inflammation, structural damage, or disease control
Sjögren’s syndrome	Three patients described across case reports	Pain, fatigue, or inflammatory markers reportedly improved in some cases	Benefit for dry eyes, dry mouth, organ involvement, or the wider Sjögren’s population
Psoriasis	Uncontrolled cohort, small case series, and case reports	Some patients reported or demonstrated improvement	Placebo controlled efficacy, durable response, or benefit for psoriatic arthritis
Systemic sclerosis and dermatomyositis	Very small case reports and series focused mainly on itching or skin symptoms	Improvement in pruritus was reported	Control of the underlying systemic autoimmune disease
Hashimoto’s disease and lupus	No persuasive condition specific clinical trial evidence located	Online claims exceed the published human evidence	Efficacy, disease modification, or a standard role in treatment

The table is not a ranking of which patients should receive LDN. It is a comparison of the type and strength of published evidence.

What Is Low Dose Naltrexone?

Naltrexone is an opioid receptor antagonist. FDA approved oral naltrexone tablets are used as part of the treatment of alcohol dependence and to block the effects of externally administered opioids.

“Low Dose Naltrexone” describes clinician directed use of naltrexone below the standard 50 mg oral tablet strength. There is no FDA defined LDN dose and no FDA approved LDN indication for autoimmune disease.

Researchers have proposed several mechanisms involving opioid signaling, immune signaling, and neuroinflammatory pathways. These remain hypotheses under investigation. A plausible mechanism does not prove that a medication improves symptoms or controls a specific disease in humans.

When a patient specific low strength is prescribed and is not available in a commercially manufactured dosage form, a compounding pharmacy may prepare it. Compounded medications are not FDA approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. Review FDA’s compounding questions and answers.

Crohn’s Disease: The Most Direct Autoimmune Related Evidence

Crohn’s disease has some of the most clinically direct LDN research in an immune mediated condition.

In a 2011 randomized, double blind, placebo controlled trial, 40 adults with moderate to severe active Crohn’s disease received 4.5 mg of naltrexone or placebo for 12 weeks. A clinical response, defined as at least a 70 point reduction in the Crohn’s Disease Activity Index, occurred in 88% of participants assigned to naltrexone and 40% assigned to placebo. An endoscopic response occurred in 78% and 28%, respectively. The trial also reported histologic improvement. Review the adult randomized trial.

Those numbers sound compelling, but the study was small and conducted at one center. Clinical remission was not clearly established as superior to placebo, and the trial was not large enough to determine long term safety, sustained remission, or how LDN compares with established Crohn’s treatments.

A pediatric pilot enrolled 14 children and used an initial randomized placebo controlled phase followed by open label treatment. Disease activity scores improved during naltrexone exposure, but the small sample and crossover design limit certainty. Review the pediatric pilot.

A Cochrane review assessed the small adult and pediatric trials and concluded that the evidence was insufficient for firm conclusions. The overall certainty was rated low because the trials involved very few patients and produced imprecise estimates. Read the Cochrane review.

What this means: Crohn’s disease has a genuine clinical signal worth studying, including objective endoscopic findings. It does not yet have the large, replicated evidence needed to position LDN as a proven replacement for established inflammatory bowel disease therapy.

Multiple Sclerosis: Mixed Symptom and Quality of Life Findings

Multiple sclerosis, or MS, is one of the conditions most commonly associated with LDN online. Published research has focused primarily on tolerability, symptoms, and quality of life, not on whether LDN prevents relapses or slows neurologic damage.

One double blind crossover trial enrolled 80 people with MS, with 60 completing the trial. LDN improved selected mental health quality of life measures, pain effects, and perceived cognitive function. It did not improve fatigue or physical quality of life measures. Review the trial.

A separate randomized placebo controlled crossover trial involving 96 people with relapsing remitting or secondary progressive MS found no consistent benefit across quality of life domains. Review the second trial.

An open label six month study in 40 people with primary progressive MS reported reduced spasticity, but pain increased and fatigue and depression did not significantly change. Because there was no placebo group, the study cannot establish that LDN caused the observed changes. Review the progressive MS pilot.

The National Multiple Sclerosis Society summarizes the distinction well: completed studies generally suggest LDN is tolerated, but it has not been shown to alter the MS disease process. Read the National MS Society overview.

What this means: LDN research in MS does not establish fewer relapses, slower disability progression, or a substitute for FDA approved disease modifying therapy. Symptom or quality of life questions should be separated from disease modification.

Rheumatoid Arthritis: Association Is Not Proof of Disease Control

Research involving rheumatoid and seropositive arthritis illustrates why study design matters.

A nationwide Norwegian prescription database study followed 360 people with rheumatoid or seropositive arthritis before and after they started LDN. Among persistent LDN users, the total amount of examined medication dispensed fell by 13%, and analgesic dispensing fell by 23%. The study also identified changes in the proportion of patients receiving certain disease modifying drugs.

However, prescription dispensing was used as a proxy for clinical improvement. The study did not directly measure swollen joints, inflammatory markers, imaging progression, function, or remission. Participants were not randomly assigned, and there was no unexposed control group. Reduced dispensing therefore cannot prove that LDN controlled rheumatoid arthritis. Review the prescription database study.

A later randomized crossover pilot included 23 people with osteoarthritis or inflammatory arthritis and evaluated chronic pain. The study did not find LDN effective for nociceptive arthritis pain overall, and the sample was too small to determine whether a specific inflammatory arthritis subgroup responded differently. Review the arthritis pilot.

What this means: The available evidence does not establish that LDN reduces rheumatoid inflammation or prevents joint damage. Patients should not stop methotrexate, biologic therapy, corticosteroids, or other prescribed treatment based on an observational association.

Sjögren’s Syndrome: Three Patients Are Not a Clinical Trial

Sjögren’s syndrome evidence is limited to three patients described in published case reports.

Those reports described improvements in musculoskeletal pain, fatigue, or selected inflammatory markers after LDN was introduced. Importantly, dry eye and dry mouth symptoms did not consistently improve. Review the first case report and the additional cases.

Case reports can identify a research question, but they cannot estimate how often a treatment works, compare it with placebo, or exclude coincidence and reporting bias.

What this means: It is accurate to say LDN has been reported in Sjögren’s syndrome. It is not accurate to present three cases as proof of efficacy for the broader Sjögren’s population.

Psoriasis: Preliminary, Uncontrolled Evidence

Psoriasis has more published patients than Sjögren’s syndrome, but the evidence remains uncontrolled.

One cohort involving 71 patients reported reductions in psoriasis severity, affected body surface area, and quality of life scores after three months of LDN. A separate 15 patient case series reported marked improvement in eight patients, some improvement in two, and no change in five. Review the 15 patient case series.

Without randomization and a placebo group, these studies cannot separate medication effects from natural symptom fluctuation, concurrent treatment, regression to the mean, or expectation effects. The published research also does not establish that LDN treats psoriatic arthritis.

What this means: Psoriasis findings are hypothesis generating. They are not equivalent to replicated randomized trial evidence.

Systemic Sclerosis and Dermatomyositis: Symptom Reports, Not Disease Modification

Very small reports have described LDN use for pruritus, or severe itching, associated with systemic sclerosis and dermatomyositis. In a three patient systemic sclerosis case series, improvement in itching was reported. Other reports describe selected skin symptom responses in dermatomyositis.

These reports address a symptom in a handful of patients. They do not establish that LDN controls the underlying connective tissue disease, prevents organ complications, or replaces immunomodulatory treatment. Review the rheumatologic evidence summary.

What About Hashimoto’s Disease and Lupus?

Hashimoto’s disease and lupus are frequently included in online lists of “conditions treated with LDN.” That wording is stronger than the available condition specific human evidence.

The absence of persuasive clinical trial evidence does not prove that LDN can never help an individual symptom. It means there is not enough evidence to estimate benefit, identify likely responders, compare LDN with established treatment, or claim that it modifies either disease.

For Hashimoto’s disease, appropriate evaluation still depends on thyroid function, symptoms, thyroid hormone needs, and other patient specific factors. For lupus, treatment decisions depend heavily on disease activity and which organs are involved. Neither condition should be reduced to a generic promise of “immune balance.”

Does LDN “Balance” or “Reset” the Immune System?

Claims that LDN “resets,” “normalizes,” or “balances” the immune system are common, but they are not measurable clinical outcomes.

The immune system is not a single dial that can simply be turned up or down. A clinically useful question is more specific:

1. Did pain or fatigue improve?

2. Did a validated disease activity score change?

3. Did inflammatory markers improve?

4. Did imaging, endoscopy, or another objective measure improve?

5. Did the response persist?

6. Did the patient reduce another treatment safely under clinician supervision?

7. Was the outcome better than placebo or usual care?

Condition specific endpoints are more informative than broad immune language.

Could LDN Replace Standard Autoimmune Treatment?

Current evidence does not support using LDN as a general replacement for established autoimmune treatment.

This distinction matters because a person may feel better while the underlying disease remains active. Pain, fatigue, sleep, and quality of life are important outcomes, but they are not always reliable measures of inflammation, tissue injury, or disease progression.

For example:

1. A person with MS can report improved mood while neurologic disease remains active.

2. A person with Crohn’s disease can experience fewer symptoms without complete mucosal healing.

3. A person with rheumatoid arthritis can report less pain while joint inflammation continues.

4. A person with lupus can feel less fatigue while kidney or blood abnormalities require treatment.

Any LDN discussion should define whether the goal is symptom support, disease activity improvement, or both.

Questions to Ask Before Considering LDN

Patients considering LDN with a qualified prescriber should ask:

1. What evidence exists for my exact diagnosis?

2. Was the research randomized, controlled, and large enough to be reliable?

3. Were the outcomes subjective symptoms, objective disease measures, or both?

4. Is LDN being considered for symptom support or disease modification?

5. Which established treatments should continue?

6. How will we measure response?

7. When will we decide whether the trial is helping?

8. What symptoms or laboratory changes require reassessment?

9. Have all current and recent opioid medications been reviewed?

10. How would surgery, dental care, injury, or emergency pain treatment be handled?

The Opioid Interaction Applies Regardless of the Condition

Naltrexone blocks opioid effects. It is contraindicated in patients receiving opioid analgesics, patients with current opioid dependence, and patients in acute opioid withdrawal. Opioid containing pain, cough, cold, and diarrhea medications may also be affected.

Patients should not combine LDN with opioids or attempt an opioid transition without medical direction. Planned surgery, dental procedures, emergency pain care, and recent opioid exposure should be discussed before treatment. Review current naltrexone labeling.

The Bottom Line

LDN should not be evaluated as one treatment for one category called “autoimmune disease.”

Crohn’s disease has small trials with clinical and endoscopic signals, but the evidence remains low certainty. Multiple sclerosis trials report mixed symptom and quality of life findings without proof of disease modification. Rheumatoid arthritis evidence is largely observational. Sjögren’s syndrome is represented by three reported patients. Psoriasis research is uncontrolled. Claims involving Hashimoto’s disease and lupus extend beyond persuasive condition specific clinical trial evidence.

That does not mean every LDN discussion should stop. It means the conversation should become more precise.

The right question is not, “Does LDN work for autoimmune disease?”

The better question is, “What has LDN been shown to do, in people with my specific diagnosis, using outcomes that matter?”

FAQ Package

Is LDN FDA approved for autoimmune disease?

No. Naltrexone is FDA approved for specific alcohol and opioid related indications. Lower dose use for autoimmune, immune mediated, pain, or inflammatory conditions is off label. A compounded LDN preparation is not FDA approved.

Which autoimmune condition has the strongest LDN evidence?

Among commonly discussed immune mediated conditions, Crohn’s disease has some of the most direct clinical evidence, including a small adult placebo controlled trial with clinical, endoscopic, and histologic outcomes. The evidence remains low certainty because the studies are small and have not been adequately replicated.

Does LDN slow multiple sclerosis progression?

Current research has not established that LDN reduces relapses, slows disability progression, or changes the MS disease process. Small studies have reported mixed findings involving quality of life and selected symptoms.

Has LDN been studied for rheumatoid arthritis?

Yes, but the evidence is limited. A Norwegian prescription database study found reduced dispensing of several medications among persistent LDN users, but it did not directly measure disease control. A small arthritis pain trial did not demonstrate significant benefit overall.

Has LDN been studied for Sjögren’s syndrome?

Published evidence consists of three patients described across case reports. Some pain, fatigue, or laboratory improvements were reported, but dry eye and dry mouth symptoms did not consistently improve. Case reports cannot establish general efficacy.

Does LDN work for psoriasis?

Small uncontrolled studies and case reports describe improvement in some patients. Placebo controlled trials are still needed to determine whether LDN reliably improves psoriasis and which patients, if any, are most likely to respond.

Is there clinical trial evidence for LDN in Hashimoto’s disease?

Persuasive condition specific human clinical trial evidence supporting routine LDN use for Hashimoto’s disease has not been established. Online use and testimonials should not be confused with controlled evidence.

Can LDN replace an immunosuppressant or biologic?

Current evidence does not support broadly replacing established autoimmune treatment with LDN. Changes to immunosuppressants, biologics, thyroid medication, or other disease specific treatment should be made only by the treating clinician.

Can LDN be taken with opioid pain medication?

Naltrexone blocks opioid effects and may precipitate withdrawal in a person who is opioid dependent. Current and recent opioid exposure must be reviewed by a qualified clinician before LDN is started.

How should an LDN trial be evaluated?

The patient and prescriber should define the exact target, such as pain, fatigue, function, disease activity, or an objective laboratory measure. They should also decide when response will be reviewed and which findings would lead to continuation, adjustment, or discontinuation.